Nocion Therapeutics, Inc.’s Post

There are some great Healthcare Investor conferences taking place this week. Are you tuning in to #Barclays and #Leerink? Check out the video below to hear why you should!

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024. Coeptis Therapeutics Dave Mehalick Dan Yerace Chris Cochran #pentoz #ceo #innovation #ai #news #newsupdate #update #january #january2024 #developmentcompany #appdevelopmentcompany #innovation2024

Exciting insights from the 19th Annual HD Therapeutics Conference! Here's a brief recap of day one of the conference.  Stay tuned for more updates!  #HDResearch #HuntingtonsDisease #HDafrica

Wrapping up the 19th Annual HD Therapeutics Conference 2024 with enlightening insights! Here's a brief recap from the final day of the conference. Stay tuned for more updates! #HDResearch #HuntingtonsDisease #ScientificAdvancements #HDAfrica

Spartan Capital Securities, LLC is excited to welcome Chromocell Therapeutics Corporation (NYSE: CHRO) as a presenting company at the Spartan Capital Investor Conference 2024, taking place on November 4th at The Pierre Hotel in New York City.   Chromocell is a pioneer in the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. The Company’s programs targeting the treatment of chronic neuropathic and acute and chronic eye pain are based on its patented core molecules. Chromocell Therapeutics Corp.'s leadership team includes Frank Knuettel II, Eric Lang, Simon P. Chandler, Richard Malamut, and Anke Hoppe. Conference attendees will be uniquely able to engage directly with Chromocell Therapeutics Corp. executives, gaining valuable insights into the company’s development and commercializing new therapeutics to alleviate pain.   This one-day event brings together public company executives, institutional investors, and capital market leaders. With over 30 presenting companies, it promises an unparalleled networking experience.   To secure your place at this premier event, visit: https://lnkd.in/enQCABXZ   #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #ChromocellTherapeutics #CHRO

We are excited to share our recent business update and highlight two key achievements: 🔹 Current Cash Balance: Allarity Therapeutics is thrilled to report a robust cash balance of $20 million, providing a runway extending into 2026 at our current burn rate. This financial stability enables us to continue our critical work without interruption. 🔹 Pausing the ATM: To safeguard our financial health and minimize shareholder dilution, we are pausing our At-The-Market (ATM) offering program for the foreseeable future. Our new management has made significant strides in enhancing our financial position and streamlining operations. We've also concentrated all our efforts on advancing stenoparib, our promising dual PARP and Tankyrase inhibitor, which continues to show promising results in Phase 2 trials. Click below to read the full press release ⬇️ #AllarityTherapeutics #BusinessUpdate #FinancialProgress #CancerResearch #Stenoparib

#Slack DMs can make it hard to track requests and measure workload impact of your #ITHelpdesk. Hear how Cohere, Xilio Therapeutics and Foqal took back control 4/17 webinar https://hubs.li/Q02pyTc90

Qatar Investment Authority (QIA) dedicated to healthtech by investing in innovative healthcare companies as well as funds Latest investment in startups: 🇺🇸 Outpace Bio (Aug 2024, Series B, $144 million, CEO Marc Lajoie) is a cell therapy company using unrivaled AI-powered protein design to program immune cells for improved function inside patients battling solid tumors 🇺🇸 Iambic Therapeutics (Jun 2024, Series B+, $50 million, CEO Thomas Miller) is a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform 🇬🇧 Autolus Therapeutics (Feb 2024, equity investment, $250 million + $350 million, CEO Christian Itin) is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies 🇮🇳 Global Dental Services (Nov 2023, equity investment, $50 million, CEO Amarinder Singh) India's largest tech-enabled-dental-platform that operates more than 400 company-owned and company-operated dental clinics under the “Clove Dental" banner 🇺🇸 BridgeBio (Sep 2023, PIPE financing, $250 million, CEO Neil Kumar) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers 🇺🇸 Star Therapeutics (Sep 2023, Series C, $90 million, CEO Adam Rosenthal) is a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need Contact QIA Healthcare Investment Team https://lnkd.in/ezbyKmtM Investment in funds: 🇶🇦🤝🇫🇷 Future French Champions (May 2024, €300 million) is a joint-venture between Qatar Investment Authority (QIA) and Bpifrance that has invested almost €600 million over two phases to boost economic growth and innovation in France. As the 3rd phase, they have announced intention to increase their commitment by up to another €300 million once the current commitment is fully deployed.  The strategic priorities:  🤖 Artificial Intelligence (AI) 🏿 Semiconductors ⚛️ Quantum Computing 🏥 Healthcare 🚀 Aerospace ⚡ Energy Transition This year, QIA also announced (https://lnkd.in/eARVkTBT) the creation of a $1 billion VC fund of funds to support the development of the local entrepreneurial ecosystem. The sectors of interest: 🖥 Technology 🏥 Healthcare 💳 Fintech 🎓 Edtech Contact QIA Funds Investment Team https://lnkd.in/eRVD5r7k 

#Slack DMs can make it hard to track requests and measure workload impact of your #ITHelpdesk. Hear how Cohere, Xilio Therapeutics and Foqal took back control in 4/17 webinar https://hubs.ly/Q02pyQ0V0

Spartan Capital Securities, LLC is excited to welcome Chromocell Therapeutics Corporation (NYSE: CHRO) as a presenting company at the Spartan Capital Investor Conference 2024, taking place on November 4th at The Pierre Hotel in New York City.   Chromocell is a pioneer in the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. The Company’s programs targeting the treatment of chronic neuropathic and acute and chronic eye pain are based on its patented core molecules. Chromocell Therapeutics Corp.'s leadership team includes Frank Knuettel II, Eric Lang, Simon P. Chandler, Richard Malamut, and Anke Hoppe. Conference attendees will be uniquely able to engage directly with Chromocell Therapeutics Corp. executives, gaining valuable insights into the company’s development and commercializing new therapeutics to alleviate pain.   This one-day event brings together public company executives, institutional investors, and capital market leaders. With over 30 presenting companies, it promises an unparalleled networking experience.   To secure your place at this premier event, visit: https://lnkd.in/enQCABXZ   #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #ChromocellTherapeutics #CHRO